Farmorubicin Injection

Regression in a broad spectrum of neoplastic diseases including mammary carcinoma, malignant lymphomas, soft tissue sarcomas, gastric, hepatic, pancreatic and sigma-rectum carcinomas, head and neck carcinoma, lung carcinoma, ovarian carcinoma and leukaemias.

Indications:

• malignant neoplasms breast cancer,
• bladder cancer
• Lymphoma,
• Multiple myeloma,
• Solid tumours,
• Acute leukaemias,
• Adjuvant treatment of axillary-node positive breast cancer,
• Local treatment of bladder carcinoma.
• Breast carcinoma,
• malignant lymphomas,
• soft tissue sarcoma,
• gastric,
• hepatic,
• pancreatic sigmoid; and rectum carcinomas,
• head and neck carcinoma,
• lung carcinoma,
• ovarian carcinoma
• leukemias.

Enoxaparin is a low molecular weight marketed as Lovenox or Clexane. It is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection (by a health care provider or the patient). Its use is evolving in acute coronary syndromes (ACS).

Enoxaparin is manufactured by Sanofi-Aventis and is derived from the intestinal mucosa of pigs.